CD274 and non-small cell lung carcinoma: Our results suggest that PFS and OS following treatment with sintilimab combined with anlotinib are not affected by PD‐L1 status, in line with prior studies of ICIs combined with antiangiogenic agents in patients with metastatic NSCLC.30, 32